Editorial & Opinion
أعرض في EDS

Cutaneous Eruption Associated with Sirolimus in a Child with FAS-Associated Autoimmune Lymphoproliferative Syndrome.

التفاصيل البيبلوغرافية
العنوان: Cutaneous Eruption Associated with Sirolimus in a Child with FAS-Associated Autoimmune Lymphoproliferative Syndrome.
المؤلفون: Trayer J; Department of Paediatric Immunology, Children's Health Ireland at Crumlin, Dublin, Ireland. trayerj@tcd.ie., Browne F; Department of Paediatric Dermatology, Children's Health Ireland at Crumlin, Dublin, Ireland., O'Sullivan M; Department of Histopathology, Children's Health Ireland at Crumlin, Dublin, Ireland.; Trinity College Dublin, Dublin, Ireland., Leahy TR; Department of Paediatric Immunology, Children's Health Ireland at Crumlin, Dublin, Ireland.; Trinity College Dublin, Dublin, Ireland.
المصدر: Journal of clinical immunology [J Clin Immunol] 2023 Oct; Vol. 43 (7), pp. 1537-1539. Date of Electronic Publication: 2023 Jun 28.
نوع المنشور: Letter
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Netherlands NLM ID: 8102137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2592 (Electronic) Linking ISSN: 02719142 NLM ISO Abbreviation: J Clin Immunol Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam : Springer
Original Publication: New York : Plenum, c1981-
مواضيع طبية MeSH: Autoimmune Lymphoproliferative Syndrome*/diagnosis , Autoimmune Lymphoproliferative Syndrome*/drug therapy , Autoimmune Lymphoproliferative Syndrome*/genetics , Autoimmune Diseases* , Lymphoproliferative Disorders*/diagnosis , Lymphoproliferative Disorders*/drug therapy, Humans ; Child ; Sirolimus/adverse effects ; fas Receptor/genetics ; Apoptosis
References: Tracey C, et al. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl. 2005;11(8):987–9. (PMID: 10.1002/lt.2049916035064)
Liu LS, McNiff JM, Colegio OR. Palmoplantar peeling secondary to sirolimus therapy. Am J Transplant. 2014;14(1):221–5. (PMID: 10.1111/ajt.1251124224736)
Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol. 2003;15(3):325–31. (PMID: 10.1016/S0952-7915(03)00042-612787759)
Price S, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989–99. (PMID: 10.1182/blood-2013-10-535393243983313968385)
Groth CG, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036–42. (PMID: 10.1097/00007890-199904150-0001710221490)
Bride KL, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17–28. (PMID: 10.1182/blood-2015-07-657981265041824705607)
Auricchio L, et al. Cutaneous manifestations as presenting sign of autoimmune lymphoproliferative syndrome in childhood. Dermatology. 2005;210(4):336–40. (PMID: 10.1159/00008476215942224)
Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000;57(5):437–48; quiz 449–51.
Campistol JM, et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant. 2010;24(2):149–56. (PMID: 10.1111/j.1399-0012.2010.01232.x20236129)
Schaffellner S, et al. Center experience in liver transplantation (LTX): Management of dermal side effects caused by sirolimus. Int Immunopharmacol. 2005;5(1):137–40. (PMID: 10.1016/j.intimp.2004.09.01715589473)
المشرفين على المادة: W36ZG6FT64 (Sirolimus)
0 (fas Receptor)
تواريخ الأحداث: Date Created: 20230627 Date Completed: 20230914 Latest Revision: 20230922
رمز التحديث: 20230922
DOI: 10.1007/s10875-023-01544-1
PMID: 37369913
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-2592
DOI:10.1007/s10875-023-01544-1